Analyst Price Targets — ELMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 1:13 pm | — | Roth Capital | $38.00 | $25.81 | TheFly | Electromed price target raised to $38 from $36 at Roth Capital |
| August 27, 2025 12:13 pm | Benjamin Haynor | Loop Capital Markets | $36.00 | $24.57 | StreetInsider | Lake Street Capital Markets Assumes Electromed (ELMD) at Buy |
| August 27, 2025 12:00 pm | Kyle Bauser | Roth Capital | $35.00 | $24.57 | TheFly | Electromed price target raised to $35 from $29 at Roth Capital |
Latest News for ELMD
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.
Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ELMD.
U.S. House Trading
No House trades found for ELMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.